Wells Fargo
IMRX icon

Wells Fargo’s Immuneering IMRX Stock Holding History

Wells Fargo’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$88.5K Buy
16,800
+1,800
+12% +$9.23K ﹤0.01% 5170
2025
Q4 		$98.7K Hold
15,000
– – ﹤0.01% 5395
2025
Q3 		$105K Buy
15,000
+5,000
+50% +$25.9K ﹤0.01% 5288
2025
Q2 		$33.7K Buy
+10,000
New +$17.1K ﹤0.01% 5644
2024
Q2 		– Sell
-6,974
Closed -$20.2K – 7156
2024
Q1 		$20.2K Buy
6,974
+926
+15% +$5.19K ﹤0.01% 5573
2023
Q4 		$44.5K Buy
6,048
+1,328
+28% +$8.85K ﹤0.01% 5320
2023
Q3 		$36.3K Sell
4,720
-3,568
-43% -$32.8K ﹤0.01% 5347
2023
Q2 		$84K Buy
8,288
+8,162
+6,478% +$78.5K ﹤0.01% 5145
2023
Q1 		$1.22K Buy
126
+2
+2% +$11 ﹤0.01% 6322
2022
Q4 		$601 Sell
124
-997
-89% -$8.83K ﹤0.01% 6333
2022
Q3 		$16K Buy
1,121
+1,066
+1,938% +$8.46K ﹤0.01% 5504
2022
Q2 		$0 Sell
55
-9,838
-99% -$52.5K ﹤0.01% 7116
2022
Q1 		$64K Sell
9,893
-297
-3% -$2.85K ﹤0.01% 5535
2021
Q4 		$165K Buy
10,190
+10,146
+23,059% +$247K ﹤0.01% 5373
2021
Q3 		$1K Buy
+44
New +$1.18K ﹤0.01% 6719

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wells Fargo's IMRX Position: Q1 2026 in Review

Wells Fargo increased its Immuneering (IMRX) stake by 12% in Q1 2026, buying an estimated $9.23K and bringing the position to 16,800 shares worth $88.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5170.

Wells Fargo first reported a position in IMRX in Q3 2021 and has held it in 15 quarters since. The position peaked at $165K in Q4 2021. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Wells Fargo held 16,800 shares of Immuneering worth $88.5K as of Q1 2026.
  • Wells Fargo bought 1,800 Immuneering shares in Q1 2026, an estimated $9.23K.
  • Immuneering made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5170 holding.
  • Wells Fargo first reported a position in Immuneering in Q3 2021 and has held it in 15 quarters since.
  • Wells Fargo's Immuneering position peaked at $165K in Q4 2021.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.